Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Icon is in a promising position with a strong financial performance and potential for growth due to its partnerships with top global pharmas and a focus on sustainability. However, potential risks, such as changes in regulations and the need for strong data security, should be closely monitored. Despite potential risks, Icon's solid track record and strategic initiatives make it a compelling investment opportunity.

Bears say

Icon is currently facing margin pressure due to higher-than-expected passthrough activity, which management has noted was stronger than anticipated and is now tracking above the original expectation of being roughly flat year-over-year. Additionally, Icon's exposure to large pharmaceutical clients and its efforts to prioritize and grow its presence in the mid-sized biotech space could lead to positive revenue momentum in the future. However, risks to the company's rating and share price include further accounting reviews or restatements, the potential for delays in delivering clinical trials, and the risk of data security breaches.

ICON (ICLR) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 12 analysts, ICON (ICLR) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.